title: Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
abstract: BACKGROUND
  Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment.
  
  
  OBJECTIVE
  This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis.
  
  
  METHODS
  The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept.
  
  
  RESULTS
  Of 1470 subjects, 1144 received secukinumab and 326 received etanercept. DLQI score 0/1 response rates were significantly higher for secukinumab than for etanercept at week 24. The median time to DLQI score 0/1 response was significantly shorter for secukinumab versus etanercept (12 vs 24 weeks; P < .01). The majority of secukinumab-treated subjects achieved DLQI score 0/1 response at week 24 and sustained it through week 52 along with a 90% to 100% reduction in the Psoriasis Area and Severity Index total score response.
  
  
  CONCLUSIONS
  Placebo comparisons are limited during the maintenance period because of rerandomization at week 12.
  
  
  CONCLUSIONS
  Secukinumab treatment provided faster and greater sustained improvements in quality of life than etanercept over 52 weeks, consistent with greater clinical response.
authors.affiliation: University of Connecticut, Farmington, Connecticut; Probity Medical Research, Waterloo, Ontario, Canada.
authors.forename: Bruce
authors.initials: B
authors.lastname: Strober
authors.affiliation: New York Medical College, Valhalla, New York.
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
authors.affiliation: RTI Health Solutions, Research Triangle Park, North Carolina.
authors.forename: Bintu
authors.initials: B
authors.lastname: Sherif
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Patrick
authors.initials: P
authors.lastname: Mollon
authors.affiliation: Novartis Pharma AG, Basel, Switzerland. Electronic address: isabelle.gilloteau@novartis.com.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gilloteau
authors.affiliation: RTI Health Solutions, Research Triangle Park, North Carolina.
authors.forename: Lori
authors.initials: L
authors.lastname: McLeod
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Todd
authors.initials: T
authors.lastname: Fox
authors.affiliation: RTI Health Solutions, Ann Arbor, Michigan.
authors.forename: Margaret
authors.initials: M
authors.lastname: Mordin
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
authors.forename: Ari
authors.initials: A
authors.lastname: Gnanasakthy
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Charis
authors.initials: C
authors.lastname: Papavassilis
authors.affiliation: Mt Sinai Medical Center, New York, New York.
authors.forename: Mark G
authors.initials: MG
authors.lastname: Lebwohl
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D012008:Recurrence; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; C508717:IL17A protein, human; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; C555450:secukinumab; D000068800:Etanercept
keywords: Dermatology Life Quality Index; patient-reported outcome; psoriasis; secukinumab